In the UK, using ALK+ NSCLC data as a proxy for ROS1+ NSCLC, NICE did not report the incremental benefits and costs separately, but reported an ICER around £50,000/ QALY gained, which is above their threshold for commonly-accepted willingness-to-pay [22]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.